Development and in vitro-in vivo evaluation of polymeric implants for continuous systemic delivery of curcumin

Pharmaceutical Research

Volumn 28, Issue 5, 2011, Pages 1121-1130

  Bansal, Shyam S ^a,b   Vadhanam, Manicka V ^b   Gupta, Ramesh C ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

bioavailability; chemoprevention; controlled release; curcumin; implants

Indexed keywords

CURCUMIN; CYCLODEXTRIN; CYTOCHROME P450 1A1; GLUTATHIONE TRANSFERASE; MACROGOL 8000; POLOXAMER; POLYCAPROLACTONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG IMPLANT; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG RELEASE; ENZYME INDUCTION; EQUIPMENT DESIGN; FEMALE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CURCUMIN; CYTOCHROME P-450 CYP1A1; DELAYED-ACTION PREPARATIONS; ENZYME INHIBITORS; FEMALE; LIVER; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79955614848     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0375-z     Document Type: Article

References (44)

1. G Bar-Sela R Epelbaum M Schaffer 2010 Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications Curr Med Chem. 17 190 197 20214562 10.2174/092986710790149738 1:CAS:528:DC%2BC3cXhsVSls7k%3D
2. BB Aggarwal A Kumar AC Bharti 2003 Anticancer potential of curcumin: preclinical and clinical studies Anticancer Res. 23 363 398 12680238 1:CAS:528:DC%2BD3sXislaqtLo%3D (Pubitemid 36361976)
3. P Anand SG Thomas AB Kunnumakkara C Sundaram KB Harikumar B Sung, et al. 2008 Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature Biochem Pharmacol. 76 1590 1611 18775680 10.1016/j.bcp.2008. 08.008 1:CAS:528:DC%2BD1cXhtl2qtb7I
4. BB Aggarwaland KB Harikumar 2009 Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases Int J Biochem Cell Biol. 41 40 59 10.1016/j.biocel.2008.06.010
5. BB Aggarwal 2000 Apoptosis and nuclear factor-kappa B: a tale of association and dissociation Biochem Pharmacol. 60 1033 1039 11007939 10.1016/S0006-2952(00)00393-2 1:CAS:528:DC%2BD3cXmslOjsLs%3D
6. MH Pan TM Huang JK Lin 1999 Biotransformation of curcumin through reduction and glucuronidation in mice Drug Metab Dispos. 27 486 494 10101144 1:CAS:528:DyaK1MXislSht7Y%3D
7. GM Holder JL Plummer AJ Ryan 1978 The metabolism and excretion of curcumin (1, 7-bis-(4-hydroxy-3-methoxyphenyl)-1, 6-heptadiene-3, 5-dione) in the rat Xenobiotica 8 761 768 726520 10.3109/00498257809069589 1:CAS:528:DyaE1MXks1yhs7k%3D (Pubitemid 9119050)
8. L Baum CW Lam SK Cheung T Kwok V Lui J Tsoh, et al. 2008 Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease J Clin Psychopharmacol. 28 110 113 18204357 10.1097/jcp.0b013e318160862c
9. AL Cheng CH Hsu JK Lin MM Hsu YF Ho TS Shen, et al. 2001 Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions Anticancer Res. 21 2895 2900 11712783 1:CAS:528: DC%2BD3MXovVWgtrg%3D
10. N Dhillon BB Aggarwal RA Newman RA Wolff AB Kunnumakkara JL Abbruzzese, et al. 2008 Phase II trial of curcumin in patients with advanced pancreatic cancer Clin Cancer Res. 14 4491 4499 18628464 10.1158/1078-0432.CCR-08-0024 1:CAS:528:DC%2BD1cXosFGitLw%3D
11. G Garcea DJ Jones R Singh AR Dennison PB Farmer RA Sharma, et al. 2004 Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration Br J Cancer. 90 1011 1015 14997198 10.1038/sj.bjc.6601623 1:CAS:528:DC%2BD2cXhslWrsLw%3D (Pubitemid 38499692)
12. K Shahani SK Swaminathan D Freeman A Blum L Ma J Panyam 2010 Injectable sustained release microparticles of curcumin: a new concept for cancer chemoprevention Cancer Res. 70 4443 4452 20460537 10.1158/0008-5472.CAN-09-4362 1:CAS:528:DC%2BC3cXmslWgtrc%3D
13. Z Ma A Haddadi O Molavi A Lavasanifar R Lai J Samuel 2008 Micelles of poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization, stabilization, and controlled delivery of curcumin J Biomed Mater Res A. 86 300 310 17957721 (Pubitemid 351969628)
14. RL Thangapazham A Puri S Tele R Blumenthal RK Maheshwari 2008 Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells Int J Oncol. 32 1119 1123 18425340 1:CAS:528:DC%2BD1cXmtlSntLk%3D
15. J Shaikh DD Ankola V Beniwal D Singh MN Kumar 2009 Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer Eur J Pharm Sci. 37 223 230 19491009 10.1016/j.ejps.2009.02.019 1:CAS:528: DC%2BD1MXms1Oksrg%3D
16. K Maiti K Mukherjee A Gantait BP Saha PK Mukherjee 2007 Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats Int J Pharm. 330 155 163 17112692 10.1016/j.ijpharm.2006.09.025 1:CAS:528:DC%2BD2sXntFSnsw%3D%3D (Pubitemid 46097368)
17. JP Jain S Modi AJ Domb N Kumar 2005 Role of polyanhydrides as localized drug carriers J Control Release. 103 541 563 15820403 10.1016/j.jconrel.2004.12. 021 1:CAS:528:DC%2BD2MXivFKhtbo%3D (Pubitemid 40476140)
18. AE Hafeman B Li T Yoshii K Zienkiewicz JM Davidson SA Guelcher 2008 Injectable biodegradable polyurethane scaffolds with release of platelet-derived growth factor for tissue repair and regeneration Pharm Res. 25 2387 2399 18516665 10.1007/s11095-008-9618-z 1:CAS:528:DC%2BD1cXhtFOru7zO
19. Z Ghalanbor M Korber R Bodmeier 2010 Improved lysozyme stability and release properties of poly(lactide-co-glycolide) implants prepared by hot-melt extrusion Pharm Res. 27 371 379 20033474 10.1007/s11095-009-0033-x 1:CAS:528:DC%2BC3cXisFamuw%3D%3D
20. P Kumar Naraharisetti B Yung Sheng Ong J Wei Xie T Kam Yiu Lee CH Wang NV Sahinidis 2007 In vivo performance of implantable biodegradable preparations delivering Paclitaxel and Etanidazole for the treatment of glioma Biomaterials 28 886 894 17067667 10.1016/j.biomaterials.2006.09.044 (Pubitemid 44667027)
21. WM Saltzmanand LK Fung 1997 Polymeric implants for cancer chemotherapy Adv Drug Deliv Rev. 26 209 230 10.1016/S0169-409X(97)00036-7 (Pubitemid 27289535)
22. AB Dhanikulaand R Panchagnula 1999 Localized paclitaxel delivery Int J Pharm. 183 85 100 10.1016/S0378-5173(99)00087-3 (Pubitemid 29257954)
23. AK Dashand GC Cudworth 2nd 1998 Therapeutic applications of implantable drug delivery systems J Pharmacol Toxicol Methods. 40 1 12 10.1016/S1056- 8719(98)00027-6 (Pubitemid 29062900)
24. C Li L Cheng Y Zhang S Guo W Wu 2010 Effects of implant diameter, drug loading and end-capping on praziquantel release from PCL implants Int J Pharm. 386 23 29 19895876 10.1016/j.ijpharm.2009.10.046 1:CAS:528: DC%2BC3cXmvFWitA%3D%3D
25. CG Pitt AR Jeffcoat RA Zweidinger A Schindler 1979 Sustained drug delivery systems. I. The permeability of poly(epsilon-caprolactone), poly(DL-lactic acid), and their copolymers J Biomed Mater Res. 13 497 507 438232 10.1002/jbm.820130313 1:CAS:528:DyaE1MXktV2nt7w%3D (Pubitemid 9152983)
26. Woodruffand MA, Hutmacher DW. The return of a forgotten polymer-polycaprolactone in the 21st century. Progress in Polymer Science. In Press, Corrected Proof.
27. WW Quitschke 2008 Differential solubility of curcuminoids in serum and albumin solutions: implications for analytical and therapeutic applications BMC Biotechnol. 8 84 18990234 10.1186/1472-6750-8-84
28. S Ravoori MV Vadhanam S Sahoo C Srinivasan RC Gupta 2007 Mammary tumor induction in ACI rats exposed to low levels of 17beta-estradiol Int J Oncol. 31 113 120 17549411 1:CAS:528:DC%2BD2sXot1Kqu7c%3D
29. PK Smith RI Krohn GT Hermanson AK Mallia FH Gartner MD Provenzano, et al. 1985 Measurement of protein using bicinchoninic acid Anal Biochem. 150 76 85 3843705 10.1016/0003-2697(85)90442-7 1:CAS:528:DyaL2MXlsFKksL0%3D (Pubitemid 16258399)
30. SS Bansal AM Kaushal AK Bansal 2008 Co-relationship of physical stability of amorphous dispersions with enthalpy relaxation Pharmazie. 63 812 814 19069241 1:CAS:528:DC%2BD1cXhsVSlsr7J
31. Y Lemmouchi E Schacht C Lootens 1998 In vitro release of trypanocidal drugs from biodegradable implants based on poly([var epsilon]-caprolactone) and poly(-lactide) J Control Release 55 79 85 9795018 10.1016/S0168-3659(98)00021-2 1:CAS:528:DyaK1cXmslWjs74%3D (Pubitemid 28477566)
32. A Rothen-Weinhold K Besseghir R Gurny 1997 Analysis of the influence of polymer characteristics and core loading on the in vivo release of a somatostatin analogue Eur J Pharm Sci 5 303 313 10.1016/S0928-0987(97)00022-5 1:CAS:528:DyaK2sXnsFyqsr8%3D (Pubitemid 27472907)
33. BD Weinberg E Blanco J Gao 2008 Polymer implants for intratumoral drug delivery and cancer therapy J Pharm Sci. 97 1681 1702 17847077 10.1002/jps.21038 1:CAS:528:DC%2BD1cXltlenu7s%3D
34. CG Pitt MM Gratzl AR Jeffcoat R Zweidinger A Schindler 1979 Sustained drug delivery systems II: factors affecting release rates from poly(epsilon-caprolactone) and related biodegradable polyesters J Pharm Sci. 68 1534 1538 529046 10.1002/jps.2600681219 1:CAS:528:DyaL3cXpvFGhtA%3D%3D (Pubitemid 10183441)
35. P Costaand JM Sousa Lobo 2001 Modeling and comparison of dissolution profiles Eur J Pharm Sci. 13 123 133 10.1016/S0928-0987(01)00095-1 (Pubitemid 32288781)
36. Rosenberg Rachel T, Siegel Steven P, Dan N. Effect of drug loading on the rate of nicotine release from poly(?-caprolactone) matrices. Polymer degradation and performance, vol. 1004. American Chemical Society; 2009. pp. 52-59.
37. KG Desai SR Mallery SP Schwendeman 2008 Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(DL-lactide-co- glycolide) implants Eur J Pharm Biopharm. 70 187 198 18472254 10.1016/j.ejpb.2008.03.007 1:CAS:528:DC%2BD1cXhtVOitrjJ
38. Kipp J, Rabinow B, Gokarn Y. Excipient selection and criteria for injectable dosage forms. Excipient development for pharmaceutical, biotechnology, and drug delivery systems, vol. null. Informa Healthcare, 2006.
39. G Ma C Song H Sun J Yang X Leng 2006 A biodegradable levonorgestrel- releasing implant made of PCL/F68 compound as tested in rats and dogs Contraception. 74 141 147 16860052 10.1016/j.contraception.2006.02.013 1:CAS:528:DC%2BD28XntFajsLk%3D (Pubitemid 44062470)
40. X Zhang KB McAuley MFA Goosen 1995 Towards prediction of release profiles of antibiotics from coated poly(-lactide) cylinders J Control Release 34 175 179 10.1016/0168-3659(94)00124-D 1:CAS:528:DyaK2MXlsFCrurw%3D
41. RA Sharma WP Steward AJ Gescher 2007 Pharmacokinetics and pharmacodynamics of curcumin Adv Exp Med Biol. 595 453 470 17569224 10.1007/978-0-387-46401-5-20
42. VK Goud K Polasa K Krishnaswamy 1993 Effect of turmeric on xenobiotic metabolising enzymes Plant Foods Hum Nutr. 44 87 92 8332589 10.1007/BF01088486 1:CAS:528:DyaK3sXmtVantL0%3D
43. S Safe F Wang W Porter R Duan A McDougal 1998 Ah receptor agonists as endocrine disruptors: antiestrogenic activity and mechanisms Toxicol Lett. 102-103 343 347 10022276 10.1016/S0378-4274(98)00331-2 (Pubitemid 29021243)
44. G Shoba D Joy T Joseph M Majeed R Rajendran PS Srinivas 1998 Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers Planta Med. 64 353 356 9619120 10.1055/s-2006-957450 1:CAS:528: DyaK1cXjtFGhtrg%3D (Pubitemid 28234275)